167 related articles for article (PubMed ID: 36627466)
1. Patient-Derived Organoids from Locally Advanced Gastric Adenocarcinomas Can Predict Resistance to Neoadjuvant Chemotherapy.
Yoon C; Lu J; Kim BJ; Cho SJ; Kim JH; Moy RH; Ryeom SW; Yoon SS
J Gastrointest Surg; 2023 Apr; 27(4):666-676. PubMed ID: 36627466
[TBL] [Abstract][Full Text] [Related]
2. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
[TBL] [Abstract][Full Text] [Related]
3. Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold.
Schmäche T; Fohgrub J; Klimova A; Laaber K; Drukewitz S; Merboth F; Hennig A; Seidlitz T; Herbst F; Baenke F; Ada AM; Groß T; Wenzel C; Ball CR; Praetorius C; Schmidt T; Ringelband-Schilling B; Koschny R; Stenzinger A; Roeder I; Jaeger D; Zeissig S; Welsch T; Aust D; Glimm H; Folprecht G; Weitz J; Haag GM; Stange DE
Mol Cancer; 2024 Jan; 23(1):10. PubMed ID: 38200602
[TBL] [Abstract][Full Text] [Related]
4. Organoids from patient biopsy samples can predict the response of BC patients to neoadjuvant chemotherapy.
Shu D; Shen M; Li K; Han X; Li H; Tan Z; Wang Y; Peng Y; Tang Z; Qu C; Jin A; Liu S
Ann Med; 2022 Dec; 54(1):2581-2597. PubMed ID: 36194178
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic Cancer Patient-derived Organoids Can Predict Response to Neoadjuvant Chemotherapy.
Demyan L; Habowski AN; Plenker D; King DA; Standring OJ; Tsang C; St Surin L; Rishi A; Crawford JM; Boyd J; Pasha SA; Patel H; Galluzzo Z; Metz C; Gregersen PK; Fox S; Valente C; Abadali S; Matadial-Ragoo S; DePeralta DK; Deutsch GB; Herman JM; Talamini MA; Tuveson DA; Weiss MJ
Ann Surg; 2022 Sep; 276(3):450-462. PubMed ID: 35972511
[TBL] [Abstract][Full Text] [Related]
6. Gastric cancer patient-derived organoids model for the therapeutic drug screening.
Xu J; Gong J; Li M; Kang Y; Ma J; Wang X; Liang X; Qi X; Yu B; Yang J
Biochim Biophys Acta Gen Subj; 2024 Apr; 1868(4):130566. PubMed ID: 38244703
[TBL] [Abstract][Full Text] [Related]
7. Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing.
Zu M; Hao X; Ning J; Zhou X; Gong Y; Lang Y; Xu W; Zhang J; Ding S
Biomed Pharmacother; 2023 Jul; 163():114751. PubMed ID: 37105073
[TBL] [Abstract][Full Text] [Related]
8. The effects of neoadjuvant chemotherapy on resectability of locally-advanced gastric adenocarcinoma: a clinical trial.
Hashemzadeh S; Pourzand A; Somi MH; Zarrintan S; Javad-Rashid R; Esfahani A
Int J Surg; 2014 Oct; 12(10):1061-9. PubMed ID: 25157992
[TBL] [Abstract][Full Text] [Related]
9. Construction of gastric cancer patient-derived organoids and their utilization in a comparative study of clinically used paclitaxel nanoformulations.
Zou J; Wang S; Chai N; Yue H; Ye P; Guo P; Li F; Wei B; Ma G; Wei W; Linghu E
J Nanobiotechnology; 2022 May; 20(1):233. PubMed ID: 35585597
[TBL] [Abstract][Full Text] [Related]
10. Establishment of Patient-Derived Gastric Cancer Organoid Model From Tissue Obtained by Endoscopic Biopsies.
Song H; Park JY; Kim JH; Shin TS; Hong SA; Huda MN; Kim BJ; Kim JG
J Korean Med Sci; 2022 Jul; 37(28):e220. PubMed ID: 35851862
[TBL] [Abstract][Full Text] [Related]
11. Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment.
Hennig A; Baenke F; Klimova A; Drukewitz S; Jahnke B; Brückmann S; Secci R; Winter C; Schmäche T; Seidlitz T; Bereuter JP; Polster H; Eckhardt L; Schneider SA; Brückner S; Schmelz R; Babatz J; Kahlert C; Distler M; Hampe J; Reichert M; Zeißig S; Folprecht G; Weitz J; Aust D; Welsch T; Stange DE
J Pathol; 2022 Aug; 257(5):607-619. PubMed ID: 35373359
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study.
Shitara K; Rha SY; Wyrwicz LS; Oshima T; Karaseva N; Osipov M; Yasui H; Yabusaki H; Afanasyev S; Park YK; Al-Batran SE; Yoshikawa T; Yanez P; Dib Bartolomeo M; Lonardi S; Tabernero J; Van Cutsem E; Janjigian YY; Oh DY; Xu J; Fang X; Shih CS; Bhagia P; Bang YJ;
Lancet Oncol; 2024 Feb; 25(2):212-224. PubMed ID: 38134948
[TBL] [Abstract][Full Text] [Related]
13. RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.
Lorenzen S; Biederstädt A; Ronellenfitsch U; Reißfelder C; Mönig S; Wenz F; Pauligk C; Walker M; Al-Batran SE; Haller B; Hofheinz RD
BMC Cancer; 2020 Sep; 20(1):886. PubMed ID: 32933498
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy with CPT-11 and cisplatin downstages locally advanced gastric cancer.
Newman E; Marcus SG; Potmesil M; Sewak S; Yee H; Sorich J; Hayek M; Muggia F; Hochster H
J Gastrointest Surg; 2002; 6(2):212-23; discussion 223. PubMed ID: 11992807
[TBL] [Abstract][Full Text] [Related]
15. Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients.
Chen JH; Chu XP; Zhang JT; Nie Q; Tang WF; Su J; Yan HH; Zheng HP; Chen ZX; Chen X; Song MM; Yi X; Li PS; Guan YF; Li G; Deng CX; Rosell R; Wu YL; Zhong WZ
Thorac Cancer; 2020 Aug; 11(8):2279-2290. PubMed ID: 32633046
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study.
Ott K; Sendler A; Becker K; Dittler HJ; Helmberger H; Busch R; Kollmannsberger C; Siewert JR; Fink U
Gastric Cancer; 2003; 6(3):159-67. PubMed ID: 14520529
[TBL] [Abstract][Full Text] [Related]
17. Antitumor effect of luteolin proven by patient-derived organoids of gastric cancer.
Hao X; Zu M; Ning J; Zhou X; Gong Y; Han X; Meng Q; Li D; Ding S
Phytother Res; 2023 Nov; 37(11):5315-5327. PubMed ID: 37469042
[TBL] [Abstract][Full Text] [Related]
18. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
19. Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer.
Marcus SG; Cohen D; Lin K; Wong K; Thompson S; Rothberger A; Potmesil M; Hiotis S; Newman E
J Gastrointest Surg; 2003 Dec; 7(8):1015-22; discussion 1023. PubMed ID: 14675711
[TBL] [Abstract][Full Text] [Related]
20. The potential and challenges of patient-derived organoids in guiding the multimodality treatment of upper gastrointestinal malignancies.
Busslinger GA; Lissendorp F; Franken IA; van Hillegersberg R; Ruurda JP; Clevers H; de Maat MFG
Open Biol; 2020 Apr; 10(4):190274. PubMed ID: 32259456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
